Initial Statement of Beneficial Ownership (3)
13 September 2019 - 2:22AM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Wass Loren W. |
2. Date of Event Requiring Statement (MM/DD/YYYY)
9/3/2019
|
3. Issuer Name and Ticker or Trading Symbol
Bionik Laboratories Corp. [BNKL]
|
|
(Last)
(First)
(Middle)
C/O BIONIK LABORATORIES CORP., 483 BAY STREET, N105 |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
See Remarks / |
|
(Street)
TORONTO, A6 M5G 2C9
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4) | 2. Amount of Securities Beneficially Owned
(Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) | 4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4) | 2. Date Exercisable and Expiration Date
(MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) | 6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option (Right to Buy) | (1) | 9/3/2026 | Common Stock | 5000 | $3.20 | D | |
| Explanation of Responses: |
| (1) | The options vest 1,666 on September 3, 2020, 1,667 on September 3, 2021 and 1,667 on September 3, 2022. |
Remarks:
Chief Commercialization Officer |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Wass Loren W.
C/O BIONIK LABORATORIES CORP.
483 BAY STREET, N105
TORONTO, A6 M5G 2C9 |
|
| See Remarks |
|
Signatures
|
| /s/ Loren Wass | | 9/11/2019 |
| **Signature of Reporting Person | Date |
Bionik Laboratories (CE) (USOTC:BNKL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bionik Laboratories (CE) (USOTC:BNKL)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Bionik Laboratories Corporation (CE) (OTCMarkets): 0 recent articles
More Bionik Laboratories Corp. News Articles